Skip to main content

Advertisement

SpringerLink
Log in

Glomerular disease in 2016

New advances in the treatment of glomerular disease

  • Year in Review
  • Published:

From Nature Reviews Nephrology

View current issue Sign up to alerts

Studies published in 2016 provide insights that bring us closer to achieving the goal of personalized therapy for primary glomerular diseases. Moreover, promising renal outcome data with new classes of glucose-lowering agents — SGLT2 inhibitors and GLP-1 agonists — offer new hope for patients with diabetic nephropathy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Dahan, K. et al. Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up. J. Am. Soc. Nephrol. 28, 348–358 (2016).

    Article  Google Scholar 

  2. Ruggenenti, P. et al. Anti-phospholipase A2 receptor antibody titer predicts post-rituximab outcome of membranous nephropathy. J. Am. Soc. Nephrol. 26, 2545–2558 (2015).

    Article  CAS  Google Scholar 

  3. Rauen, T. et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N. Engl. J. Med. 373, 2225–2236 (2015).

    Article  CAS  Google Scholar 

  4. Tesar, V. et al. Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study. J. Am. Soc. Nephrol. 26, 2248–2258 (2015).

    Article  CAS  Google Scholar 

  5. Faul, C. et al. The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat. Med. 14, 931–938 (2008).

    Article  CAS  Google Scholar 

  6. Sadowski, C. E. et al. A single-gene cause in 29.5% of cases of steroid-resistant nephrotic syndrome. J. Am. Soc. Nephrol. 26, 1279–1289 (2015).

    Article  CAS  Google Scholar 

  7. Buscher, A. K. et al. Rapid response to cyclosporin A and favorable renal outcome in nongenetic versus genetic steroid-resistant nephrotic syndrome. Clin. J. Am. Soc. Nephrol. 11, 245–253 (2016).

    Article  Google Scholar 

  8. Wanner, C. et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N. Engl. J. Med. 375, 323–334 (2016).

    Article  CAS  Google Scholar 

  9. Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311–322 (2016).

    Article  CAS  Google Scholar 

  10. Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834–1844 (2016).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Nephrology, Radboud University Medical Center, PO Box 9101, Nijmegen, 6500 HB, Netherlands

    Rutger J. Maas & Jack F. Wetzels

Authors
  1. Rutger J. Maas
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jack F. Wetzels
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jack F. Wetzels.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Maas, R., Wetzels, J. New advances in the treatment of glomerular disease. Nat Rev Nephrol 13, 65–66 (2017). https://doi.org/10.1038/nrneph.2016.195

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2016.195

  • Springer Nature Limited

This article is cited by

Search

Navigation